(ONNN) Board of Directors Approves $1 Billion Share Repurchase Program

ON Semiconductor (Nasdaq: ONNN), driving energy efficient innovations, today announced that its Board of Directors has approved a capital allocation policy under which the company intends to return approximately 80 percent of free cash flow less repayments of long-term debt to shareholders, subject to a variety of factors, including the company’s strategic plans, market and economic conditions, and Board of Directors’ discretion. ON Semiconductor defines free cash flow as net cash provided by operating activities less purchases of property, plant and equipment of the company and its consolidated subsidiaries.

The Board of Directors also approved a new share repurchase program under the new policy. Under the new share repurchase program, the company intends to repurchase approximately $1 billion worth of its common shares over a four year period, subject to the same factors and considerations described above. The new stock repurchase program is effective today and the $300 million stock repurchase program announced in August of 2012 has been terminated.

“The new capital allocation policy demonstrates ON Semiconductor’s strong commitment towards efficient use of capital and maximizing shareholder value,” said Keith Jackson, president and CEO of ON Semiconductor. “We believe that at current levels, our stock offers compelling value, and therefore the repurchase program should deliver substantial value to our shareholders. The long term outlook for our business remains strong, driven by a robust design win pipeline, and we are confident in our ability to generate approximately $300 million to $400 million of annual free cash flow on a sustained basis in the near to mid-term.”

Based on the closing price of the company’s common stock as of November 28 2014, the $1 billion repurchase program represents the potential repurchase of approximately 111 million shares or 25 percent of the weighted average diluted common shares outstanding at the end of the third quarter of 2014.

About ON Semiconductor

ON Semiconductor (Nasdaq: ONNN) is driving energy efficient innovations, empowering customers to reduce global energy use. The company offers a comprehensive portfolio of energy-efficient power and signal management, logic, discrete and custom solutions to help design engineers solve their unique design challenges in automotive, communications, computing, consumer, industrial, LED lighting, medical, military/aerospace and power supply applications. ON Semiconductor operates a responsive, reliable, world-class supply chain and quality program, and a network of manufacturing facilities, sales offices and design centers in key markets throughout North America, Europe, and the Asia Pacific regions. For more information, visit http://www.onsemi.com.

ON Semiconductor and the ON Semiconductor logo are registered trademarks of Semiconductor Components Industries, LLC. All other brand and product names appearing in this document are registered trademarks or trademarks of their respective holders. Although the company references its Web site in this news release, such information on the Web site is not to be incorporated herein.

Cautions regarding Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included or incorporated in this document could be deemed forward-looking statements, particularly statements about the future financial performance of ON Semiconductor. These forward-looking statements are often characterized by the use of words such as “believes,” “estimates,” “expects,” “projects,” “may,” “will,” “intends,” “plans,” “should” or “anticipates,” or by discussions of strategy, plans or intentions. All forward-looking statements in this document are made based on information available to us as of the date of this release, our current expectations, forecasts, estimates, and assumptions, and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. Among these factors are our revenues and operating performance, poor economic conditions and markets (including current financial conditions), effects of exchange rate fluctuations, the cyclical nature of the semiconductor industry, changes in demand for our products, changes in inventories at our customers and distributors, technological and product development risks, enforcement and protection of our intellectual property rights and related risks, risks related to the security of our information systems and secured network, availability of raw materials, electricity, gas, water and other supply chain uncertainties, our ability to effectively shift production to other facilities when required in order to maintain supply continuity for our customers, variable demand and the aggressive pricing environment for semiconductor products, our ability to successfully manufacture in increasing volumes on a cost-effective basis and with acceptable quality for our current products, competitor actions including the adverse impact of competitor product announcements, pricing and gross profit pressures, loss of key customers, order cancellations or reduced bookings, changes in manufacturing yields, control of costs and expenses and realization of cost savings and synergies from restructurings, significant litigation, risks associated with decisions to expend cash reserves for various uses such as debt prepayment, stock repurchases or acquisitions rather than to retain such cash for future needs, risks associated with acquisitions and dispositions (including from integrating and consolidating and timely filing financial information with the Securities and Exchange Commission for acquired businesses and difficulties encountered in accurately predicting the future financial performance of acquired businesses), risks associated with our substantial leverage and restrictive covenants in our debt agreements that may be in place from time to time, risks associated with our worldwide operations including foreign employment and labor matters associated with unions and collective bargaining arrangements as well as man-made and/or natural disasters affecting our operations and finances/financials, the threat or occurrence of international armed conflict and terrorist activities both in the United States and internationally, risks and costs associated with increased and new regulation of corporate governance and disclosure standards, risks related to new legal requirements and risks involving environmental or other governmental regulation. Information concerning additional factors that could cause results to differ materially from those projected in the forward-looking statements is contained in ON Semiconductor’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other of our filings with the Securities and Exchange Commission. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline, our intentions with respect to our stock repurchase program and capital allocation policy may not be realized, and investors could lose all or part of their investment.

Readers are cautioned not to place undue reliance on forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any subsequent date and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made.

Additional Information about the New Stock Repurchase Plan and Where to Find It

For additional information, visit ON Semiconductor’s corporate website, www.onsemi.com, or for official filings visit the SEC website, www.sec.gov.

(OTIC) Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere’s Disease

SAN DIEGO, Dec. 1, 2014 — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that the company has achieved target enrollment in its Phase 2b clinical trial of OTO-104 in patients with Ménière’s disease.

This prospective, randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of OTO-104 for the treatment of Ménière’s disease in a total of 140 patients. In the Phase 2b clinical trial, patients are observed for up to four months following a single intratympanic (IT) injection of either OTO-104 or placebo. The primary endpoint, consistent with the previous Phase 1b clinical trial, is the reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period. The clinical trial has been designed and is being conducted to serve as one of two pivotal, single-dose efficacy trials that the company expects the FDA will require to support a New Drug Application (NDA) filing for treatment of Ménière’s disease.

“We would like to thank the patients for their participation, and the clinical investigators for their support in achieving our enrollment goal for this trial,” said David A. Weber, Ph.D., president and CEO of Otonomy. “A number of potential subjects are still completing the one month lead-in period of the trial, which could result in total enrollment that will exceed 140. We continue to expect results in the second quarter of 2015.”

About OTO-104

OTO-104, which has been granted Fast Track designation by the FDA, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Ménière’s disease and other inner ear conditions. Otonomy has completed a randomized, prospective, double-blind, placebo-controlled, Phase 1b clinical trial of a single IT injection of OTO-104 in patients with Ménière’s disease. Results demonstrated that OTO-104 is well tolerated when administered as a single IT injection, and 12 mg of OTO-104 was associated with clinically meaningful improvements in both vertigo frequency and tinnitus compared to placebo three months after treatment. There were no serious adverse events observed during the clinical trial. A Phase 2b single-dose efficacy trial with approximately 140 Ménière’s disease patients is ongoing in the U.S. and Canada, with results expected in the second quarter of 2015. The company believes this trial will serve as one of two pivotal, single-dose efficacy trials required to support U.S. regulatory approval. OTO-104 is also being evaluated in a multiple-dose safety study in the United Kingdom in patients with Ménière’s disease, and the company expects the results of which will support regulatory filings in this indication.

About Ménière’s Disease

Ménière’s disease is a chronic condition characterized by acute vertigo attacks, tinnitus, fluctuating hearing loss and a feeling of aural fullness. Of these symptoms, the vertigo attacks are typically most troubling for patients since they disrupt daily activities and are difficult to anticipate and manage. In general, patients are diagnosed with unilateral Ménière’s disease in middle age and symptoms often continue for decades. Over time, the fluctuating hearing loss becomes permanent in many patients, and a subset of patients will develop symptoms in their second ear. According to the National Institute of Deafness and Other Communication Disorders, there are more than 600,000 patients diagnosed with Ménière’s disease in the United States. There is no known cure for Ménière’s disease and there are currently no FDA-approved drug treatments.

About Otonomy

Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy’s proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Ménière’s disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information, please visit www.otonomy.com.

Cautionary Note Regarding Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, the expected enrollment and timing of the results for Otonomy’s single-dose Phase 2b clinical trial of OTO-104, Otonomy’s belief that the single-dose Phase 2b clinical trial of OTO-104 will serve as one of two pivotal, single-dose efficacy trials required to support an NDA filing for the treatment of Ménière’s disease and U.S. regulatory approval, the number of clinical trials with OTO-104 required by the FDA for U.S. regulatory approval, and the Company’s expectation that the multiple-dose safety study of OTO-104 in the United Kingdom in patients with Ménière’s disease will support regulatory filings in this indication. Forward-looking statements reflect the Company’s current views with respect to certain current and future events and are subject to various risks and uncertainties that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to: expectations regarding clinical trial results for existing product candidates, future development of product candidates for additional indications, and future development of other product candidates; timing and likelihood of regulatory filings and approvals; expectations regarding adoption and use of product candidates by physicians; Otonomy’s ability to protect its intellectual property related to product candidates in the United States and throughout the world; Otonomy’s ability to manage operating expenses, capital requirements and additional financing needs; implementation of Otonomy’s business model and strategic plans for its business, products and technology; Otonomy’s dependence on third parties for development, manufacture and distribution of products; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Otonomy’s Form 10-Q filed on November 12, 2014 with the Securities and Exchange Commission (the SEC), the final prospectus related to Otonomy’s initial public offering filed with the SEC on August 13, 2014, and Otonomy’s future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Otonomy as of the date hereof. Otonomy disclaims any obligation to update any forward-looking statements, except as required by law.

CONTACT: Media Inquiries
         Canale Communications
         Heidi Chokeir, Ph.D.
         Vice President
         619.849.5377
         heidi@canalecomm.com

         Investor Inquiries
         Westwicke Partners
         Robert H. Uhl
         Managing Director
         858.356.5932
         robert.uhl@westwicke.com

(SANW) Files Patent for Unique Stevia Variety for Commercial Production

New variety possesses increased levels of Reb-A sweetener component and high plant productivity (yield) designed for the commercial production and processing market

FIVE POINTS, Calif., Dec. 1, 2014  — S&W Seed Company (Nasdaq: SANW) today announced it has filed a patent application with the U.S. Patent and Trademark Office for stevia plant variety “SW107.”  Variety SW107 exhibits increased concentrations of Reb-A sweetener, higher leaf mass production and an improved taste profile that has little or no aftertaste. SW107 has been bred to address commercial processing markets in North America, South America, and other regions of the world that have climates suitable for it.

Companies producing consumer food products, as well as ingredient manufacturers, recognize the value of stevia as an all-natural sweetener in beverage, dairy, baking and snack products. Stevia’s health benefits include zero calories and minimal glycemic impact and stability when heated. Since the primary sweetener used in stevia-based products, Reb A, comes 100% from agricultural sources, the Company believes that improved stevia varieties, like SW107, with increased yield and Reb A content will be very desirable commercially.

The Company believes SW107 is well qualified to be successful in the commercial market. SW107 has a number of differentiating factors, including enhanced leaf yield, Reb-A output, and taste profile, as well as plant vigor that includes superior overwintering and later flowering attributes compared with the majority of the plant population from which the line was derived. In field trials throughout the western United States, SW107 yielded approximately 40% more leaf, 60% more Reb-A content, and more than a 100% increase in the Reb-A to stevioside ratio, as compared to test samples from stevia varieties now in mainstream production. S&W believes these results, coupled with an improved aftertaste profile, mean that SW107 will be economically attractive to stevia farmers and to the commercial volume stevia processing community.  With the filing of this patent application, the Company will begin seeking agreements with consumer products companies, ingredient manufacturers and stevia mass processors.

Mark Grewal, chief executive officer of S&W Seed Company, commented, “This patent application marks a significant milestone in our stevia development program. With the huge growth in demand for stevia in the last five years since we entered the industry, food manufacturers and processors have expressed a desire for reliable sources of stevia leaf production outside of China. Due to the higher leaf mass of SW107, which adds to yield, the high Reb-A percentage, and its improved taste and plant vigor characteristics, we believe SW107 addresses many of the economic challenges that farmers and producers in North and South America have faced to date.”

Variety SW107 was classically bred from germplasm that is proprietary to S&W’s stevia program that first commenced in 2009 under the direction of Dr. Clint Shock, who is an internationally recognized expert on stevia. S&W’s stevia research and development team has crossed hundreds of lines of stevia plants, many of which were collected over many years, with a goal of developing stevia varieties that have unique properties for commercialization. The Company is optimistic that SW107 will be followed by other promising varieties.  S&W’s research and development team hopes to develop other new varieties that have distinctly different sets of plant attributes and can address other market needs.  SW107 initially is targeted at North and South America, where stevia plant production has been somewhat limited.

To date, stevia production and extraction has largely been based in China and, to a lesser extent, South America. SW107 initially is targeted to be produced in North America and South America, where there have been insignificant commercial quantities grown due to farming economics. S&W believes SW107 will facilitate the growth of stevia in mass commercial quantities in these regions due to its high plant productivity (yield) and enhanced levels of Reb-A to extract.

About S&W Seed Company
Founded in 1980, S&W Seed Company is a global agricultural company, headquartered in the Central Valley of California. The company is the largest producer of non-dormant alfalfa seed varieties in the world, with production operations in the San Joaquin and Imperial Valleys of California, as well as in South Australia. The company has worldwide sales and distribution through both a direct sales force as well as dealer-distributors.  The company’s proprietary varieties are designed to meet the shifting needs of farmers that require high performance in poor and highly saline soil conditions and have been verified over decades of university-sponsored trials.  Additionally, the company is utilizing its research and breeding expertise to develop and produce U.S.-based stevia leaf.  Stevia is an all-natural, zero calorie sweetener for the food and beverage industry. For more information, please visit www.swseedco.com.

Safe Harbor Statement
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in the Company’s 10-K for the fiscal year ended June 30, 2014, and other filings made by the Company with the Securities and Exchange Commission.

(CANF) Published: Potential Breakthrough for Prevention of Neuropathic Pain by CF101

PETACH TIKVA, Israel, Dec. 1, 2014 — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported newly published scientific findings conducted by St. Louis University researchers, Daniela Salvemini and colleagues in collaboration with Dr. Jacobson from the National Institutes of Health (NIH), on the prevention of neuropathic pain by CF101, generically known as IB-MECA. According to the research, the latter binds with high affinity to the A3 adenosine receptor and via specific mechanistic pathways significantly reduces neuropathic pain in animal models. Can-Fite CEO Dr. Pnina Fishman commented on these findings, stating, “It is very interesting that our drugs have additional well-defined clinical application in the field of neuropathic pain which is an unmet need. The study indicates some compelling results that relate to our CF101 and CF102 drugs. Former studies from the same group also showed similar data utilizing CF102, known as Cl-IB-MECA. In addition, this group showed earlier that CF101 prevents chemotherapy-induced peripheral neuropathy in pre-clinical studies. We believe that the A3 adenosine platform technology that we have been developing over the past decade and the excellent safety profile of the drugs has the potential to yield a unique therapy for this patient population.”

While Can-Fite holds an exclusive worldwide license from NIH for clinical development of IB-MECA and Cl-IB-MECA, these compounds may be used for basic research purposes in the lab.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite’s filings with the SEC and in its periodic filings with the TASE.  In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.  Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114

(ISR) Cesium-131 Therapy Stops Brain Cancers from Recurring

RICHLAND, WA, United States, via ETELIGIS INC., 12/01/2014 – – IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the striking results of a study of brain cancer patients treated with IsoRays Cesium-131 internal radiation (brachytherapy) cancer therapy. The findings of the study, conducted by researchers at Barrow Neurological Institute, were presented at the November 2014 annual meeting of the Society for Neuro-Oncology in Miami, Florida.

The Barrow study reported on 27 patients who had a variety of deadly brain cancers, including high grade gliomas, high grade meningiomas, and brain metastases. The patients had received an average of 2 and as many as 4 extensive earlier treatments that had failed, resulting in a recurrence of their cancers in the same locations where treatment had previously been applied.

IsoRay Chairman and CEO Dwight Babcock commented, Cancers that recur in the brain pose major problems. They have shown a resistance to the standard therapies of surgery and conventional radiation. Given the confined volume of the interior of the skull, the impact of brain tumors is debilitating. Expanding cancerous masses compress brain matter and nerves originating in the brain leading to significant and life-altering complications.

Oncologists at the prestigious Barrow Neurological Institute employed a technique developed by GammaTile, LLC that provides an intensive dose of Cesium-131-based radiation in tandem with surgical removal of these malignant growths. Following surgical removal of the tumor tissue, Cesium-131 was delivered to the targeted brain tissue using a modular, pre-commercial biocompatible carrier system that provided custom-tailored implants for each patient.

Barrow neuro-oncologist Dr. Christopher Dardis presented the data to an audience of neuro-oncologists specialists who manage the treatment of brain cancer patients. According to Dr. Dardis presentation, the patients who were treated with the new approach using Cesium-131 fared better than they had using earlier, conventional treatment. In fact, 26 of the 27 patients (96%) had not experienced a recurrence of the treated cancer within the treated bed during the follow-up period.

Barrow Neurological Institute is among the worlds foremost brain cancer research and treatment sites. The study team was led by radiation oncologist Dr. David Brachman and neurosurgeon Dr. Peter Nakaji, both internationally renowned and respected in the field of brain cancer treatment.

Dr. Brachman, who serves as Chief Technology Officer at GammaTile, LLC, said: As a rule, we dont necessarily think that the second or third line treatment would work better than the first-line treatment. But this seems to be the case here. Based on these outcomes, this new therapy successfully treated patients who failed conventional therapies and we believe that it could help many other patients.

IsoRay CEO Dwight Babcock commented, “We are extremely excited to see that Cesium-131 isotope seeds continue to perform so well against aggressive cancers throughout the body, including a variety of brain cancers as shown in this study. This further confirms other peerreviewed results showing Cesium-131 can have a very favorable impact on local control, especially for cancers that have shown a tendency to recur at the site of surgery. We remain committed to helping patients afflicted with these horrible cancers and enhancing their quality of life. The message is clear and the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients.

IsoRays various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRays cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite radiation therapy system.

About IsoRay:

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement:

Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether sales of our products will continue at historic levels or increase, whether the use of our products will increase or continue, whether we will continue to receive support from industry leaders, whether awareness of our products in the medical community will continue or increase, whether future studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.

CONTACT:

IsoRay Medical

Info@Isoray.com

(509) 375-1202

Worldwide Financial

Info@wwfinancial.com

(954) 360-9998

(FLL) Announces the Appointment of Daniel R. Lee as Chief Executive Officer

Full House Resorts, Inc. (NASDAQ:FLL), a developer and manager of gaming facilities, today announced that it has reached a favorable agreement with a group of shareholders, enhancing expertise to its management team and board.

Under the terms of the agreement, the Board has been increased from five to nine members and the Company accepted the resignations of Andre M. Hilliou and Mark J. Miller as directors and entered into Separation Agreements with respect to their employment. To fill the resulting six vacancies, W.H. Baird Garrett, Raymond Hemmig, Ellis Landau, Daniel R. Lee, Bradley M. Tirpak and Craig W. Thomas have been appointed to serve as directors, each subject to normal and customary regulatory approvals. Mr. Lee will replace Mr. Hilliou as the Company’s Chief Executive Officer.

Mr. Lee was previously the Chairman and Chief Executive Officer of Pinnacle Entertainment, a large regional casino company. In that role, he oversaw successful properties in each of the principal markets where Full House operates. Prior thereto, during the 1990s, he was the Chief Financial Officer and Senior Vice President of Finance and Development of Mirage Resorts. In various roles, he has participated in the development of numerous major casinos throughout his career, all of which have been successful. These include L’Auberge and the soon-to-open Golden Nugget in Lake Charles, Louisiana; River City and Lumiere Place in St. Louis, Missouri; Casino Magic in Neuquen, Argentina; Bellagio, Treasure Island and Monte Carlo in Las Vegas; and The Borgata in Atlantic City, New Jersey. He worked on Wall Street earlier in his career, as a Chartered Financial Analyst specializing in the casino and hotel industries. Mr. Lee has a Bachelors’ degree in Hotel Administration and a Masters degree in Business Administration, both from Cornell University.

In connection with his appointment as the Company’s Chief Executive Officer, the Company’s compensation committee of the board of directors approved the grant to Mr. Lee of a stock option to purchase 943,834 shares of the Company’s common stock at an exercise price per share equal to the closing price of Company’s common stock on the grant date. Mr. Lee’s option is scheduled to vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in substantially equal installments over the following three years (subject to full or partial accelerated vesting on a qualifying termination of employment or a change in control of the Company). The stock option was granted as a material component of Mr. Lee’s compensation and decision to enter into employment with the Company and was granted as an employment inducement award pursuant to NASDAQ Listing Rule 5635(c)(4).

As part of the agreement, Messrs. Lee, Tirpak and Thomas have withdrawn their solicitation statement calling for a special meeting of shareholders and will cease all further solicitation efforts. The settlement document will be filed with the Securities and Exchange Commission.

The Company believes that the settlement agreement is in the best interests of stockholders and resolves the issues raised by the concerned stockholder group in a favorable manner for all parties. The Company looks forward to working with the new members of the Board and management in its continued efforts to maximize stockholder value. Accordingly, and with the concurrence of the reconstituted board, the Company looks forward to continuing to work with its financial advisors to evaluate all strategic alternatives for the company.

“I would like to thank the incumbent Full House Board for working with us to position the Company for future success,” stated Full House’s new CEO, Daniel R. Lee. “I would also like to thank Andre and Mark for their many years of service with the Company and wish them well in their future endeavors. Finally, I look forward to meeting all of the Full House employees and to working together to make Full House Resorts into a strong and successful company building value for shareholders.”

About Full House Resorts, Inc.

Full House owns, develops and manages gaming facilities throughout the country. The Rising Star Riverboat Casino in Rising Sun, Indiana has 35,000 square feet of gaming space with 940 slot and video poker machines and 30 table games. The property includes 294 hotel rooms, a pavilion with five food and beverage outlets, an 18-hole Scottish links golf course and a large, multi-purpose Grand Theater for concerts and performance events as well as meetings and conventions. The Silver Slipper Casino in Hancock County, Mississippi, has 37,000 square feet of gaming space with almost 1,000 slot and video poker machines, 26 table games, and the only live Keno game on the Gulf Coast. The property includes a fine dining restaurant, buffet, quick service restaurant and two casino bars. Stockman’s Casino in Fallon, Nevada has 8,400 square feet of gaming space with approximately 265 gaming machines, four table games and a keno game. The Company also operates the Grand Lodge Casino at the Hyatt Regency Lake Tahoe Resort, Spa and Casino in Incline Village, Nevada on the north shore of Lake Tahoe under a lease agreement with the Hyatt organization. Further information about Full House Resorts can be viewed on its website at www.fullhouseresorts.com.

Forward-looking Statements

Some of the statements made in this release are forward-looking statements. These forward-looking statements are based upon Full House’s current expectations and projections about future events and generally relate to Full House’s plans, objectives and expectations for Full House’s business. Although Full House’s management believes that the plans and objectives expressed in these forward-looking statements are reasonable, the outcome of such plans, objectives and expectations involve risks and uncertainties including without limitation, regulatory approvals, including the ability to maintain a gaming license in Indiana, Nevada and Mississippi, financing sources and terms, integration of acquisitions, competition and business conditions in the gaming industry, including competition from Ohio casinos. Additional information concerning potential factors that could affect Full House’s financial condition and results of operations is included in the reports Full House files with the Securities and Exchange Commission, including, but not limited to, its Form 10-K for the most recently ended fiscal year.

(TASR) Winston-Salem PD Moves to Full Deployment of AXON Body Cameras

The City to Deploy 916 AXON Cameras and Use EVIDENCE.com to Store and Manage All Digital Evidence

SEATTLE, WA–(Nov 26, 2014) – TASER International (NASDAQ: TASR) today announced the purchase of 623 AXON body-worn video cameras and a five-year subscription to EVIDENCE.com by the Winston-Salem Police Department. This order was received in the fourth quarter of 2014 and is expected to ship in the fourth quarter of 2014.

The Winston-Salem Police Department made an initial purchase of 293 AXON cameras with a three-year subscription of EVIDENCE.com in July of this year. Due to the success of their program they decided to outfit their entire patrol division with TASER’s AXON cameras and a five-year subscription to EVIDENCE.com.

“The results we saw from our initial deployment of body cameras were very encouraging, and included better interactions between our officers and the public,” says Winston-Salem Police Chief Barry D. Rountree. “We are looking forward to having continued success with the AXON body-worn cameras and EVIDENCE.com technology from TASER as we deploy them to the entire police department’s patrol division.”

“It’s not uncommon for an agency to test our AXON cameras and EVIDENCE.com solution first to see how their officers and community respond to the new technology, said Rick Smith, CEO and founder of TASER International. “The positive results can be so readily apparent that we typically find an agency, like Winston-Salem, moving to a full deployment not long after they first deploy. We’re looking forward to supporting this agency in their deployment of our technology.”

TASER’s AXON cameras are small, yet highly visible, and can be attached securely to sunglasses, a cap, a shirt collar, or a head mount. They are powered by a pocketsize battery pack, which ensures recording capability during an entire shift. When recording, the cameras capture a wide-angle, full-color view of what an officer is facing. The video automatically uploads via a docking station to EVIDENCE.com, a cloud-based storage and management system, where it can be easily accessed for review. An end-user cannot tamper with video files stored online or on AXON video cameras.

EVIDENCE.com helps police capture, manage, and share their digital evidence without the complexity or cost of installing in-house servers. It enables greater transparency through seamless integration with the industry-leading AXON body-worn video cameras. EVIDENCE.com is the most secure, scalable, and cost-effective solution for managing all types of digital evidence. EVIDENCE.com automates the upload process to ensure security and integrity while keeping officers in the field rather than sitting at computers.

A year-long Cambridge University study conducted at the Rialto, CA Police Department investigated whether officers’ use of video cameras could bring measurable benefits to relations between police and civilians. The results showed an 88% reduction in citizen complaints and a 60% reduction in uses of force after implementation of TASER’s AXON flex cameras. In a study by Arizona State University, the Mesa Police Department’s use of AXON cameras revealed a 48% reduction in citizen complaints against camera officers for misconduct during the study period, and a 75% decline in use of force complaints. When complaints were brought to Mesa PD, they were resolved quickly due to the accessibility of video evidence.

Follow EVIDENCE.com

• Facebook: https://www.facebook.com/EVIDENCEcom
• Twitter: http://www.twitter.com/EVIDENCEcom

About TASER International, Inc.

TASER International makes communities safer with innovative public safety technologies. Founded in 1993, TASER first transformed law enforcement with its electrical weapons. TASER continues to define smarter policing with its growing suite of technology solutions, including AXON body-worn video cameras and EVIDENCE.com, a secure digital evidence management platform. More than 134,000 lives and countless dollars have been saved with TASER’s products and services.

Learn more at www.TASER.com and www.EVIDENCE.com or by calling (800) 978-2737.
TASER^® is a registered trademark of TASER International, Inc., registered in the U.S. All rights reserved. TASER logo and AXON are trademarks of TASER International, Inc.

Note to Investors

Please visit http://investor.taser.com, http://blog.taser.com, www.twitter.com/taser_ir, www.twitter.com/officialtaser and https://www.facebook.com/TASER.International where TASER discloses information from time to time about the company, its financial information, and its business.

Visit our Investor Relations Safe Harbor Statement at: http://investor.taser.com/safeHarbor.cfm

For investor relations information please contact Erin Curtis by phone at 480-515-6330 or via email at IR@TASER.com.

(BONE) to Present at the 7th Annual LD Micro Conference

BELGRADE, Mont., Nov. 26, 2014  — Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CFO, John Gandolfo, will present at the LD Micro Conference 7th Annual Main Event, to be held December 4, 2014 at the Luxe Hotel in Los Angeles, CA. Bacterin’s presentation will take place Thursday, December 4, 2014 at 1:30pm PT.

Institutional investors that wish to request a meeting with Bacterin should contact LD Micro or The Cockrell Group at 877.889.1972.

A live broadcast of the conference presentation will be available. To access the broadcast, go to the “Investor Info” section of the Company’s website at www.bacterin.com. A replay of the conference presentation will also be available.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE MKT:BONE) develops, manufactures and markets biologics products to domestic and international markets. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin’s Medical Device division develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking Statements

The presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “continue,” “efforts,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “projects,” “forecasts,” “strategy,” “will,” “goal,” “target,” “prospects,” “potential,” “optimistic,” “confident,” “likely,” “probable” or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward- looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company’s secured lending facility; the Company’s ability to manage cash flow and achieve profitability; the Company’s ability to remain listed on the NYSE MKT; the Company’s ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company’s sales force to achieve expected results; the ability of the Company’s customers to pay and the timeliness of such payments; the Company’s ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company’s ability to attract and retain management and employees with appropriate skills and expertise; the Company’s ability to successfully conclude government investigations; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading “Risk Factors.” The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: COCKRELL GROUP
         877.889.1972
         investorrelations@thecockrellgroup.com
         cockrellgroup.com

(DCIX) Direct Continuation of Time Charter Agreements for m/v Cap Domingo, Doukato

ATHENS, Greece, Nov. 26, 2014  — Diana Containerships Inc. (Nasdaq:DCIX), (the “Company”), a global shipping company specializing in the ownership of containerships, today announced that, through two separate wholly-owned subsidiaries, it has agreed to extend the present time charter contracts for two of its Panamax container vessels, the m/v Cap Domingo and the m/v Cap Doukato.

The charterers, Reederei Santa Containerschiffe GmbH & Co. KG, have agreed to novate each of the present time charter contracts to Rudolf A. Oetker KG. The gross charter rate will be US$9,900 per day, minus a 3.75% commission paid to third parties for a period of thirteen (13) months (minus thirty (30) plus forty-five (45) days) for m/v Cap Domingo and for a period of minimum thirteen (13) months to maximum sixteen (16) months for m/v Cap Doukato. The new charter period for both vessels will commence on December 23, 2014.

The employments of the two aforementioned vessels are anticipated to generate approximately US$7.43 million of gross revenue for the minimum scheduled period of the time charters.

The Cap Domingo and Cap Doukato are both container vessels of 3,739 TEU capacity built in 2001 and 2002, respectively.

Diana Containerships Inc.’s fleet currently consists of 10 container vessels (4 Post-Panamax and 6 Panamax) as well as a Panamax container vessel expected to be delivered to the Company by the end of November 2014. A table describing the current Diana Containerships Inc. fleet can be found on the Company’s website, www.dcontainerships.com. Information included on the Company’s website does not constitute a part of this press release.

About the Company

Diana Containerships Inc. is a leading global provider of shipping transportation services through its ownership of containerships. The Company’s vessels are employed primarily on time charters with leading liner companies carrying containerized cargo along worldwide shipping routes.

Cautionary Statement Regarding Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for containership capacity, changes in our operating expenses, including bunker prices, drydocking and insurance costs, the market for our vessels, availability of financing and refinancing, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessel breakdowns and instances of off-hires and other factors. Please see our filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.

CONTACT: Corporate Contact:
         Ioannis Zafirakis
         Director, Chief Operating Officer and Secretary
         Telephone: +30-216-600-2400
         Email: izafirakis@dcontainerships.com
         Website: www.dcontainerships.com

         Investor and Media Relations:
         Edward Nebb
         Comm-Counsellors, LLC
         Telephone: + 1-203-972-8350
         Email: enebb@optonline.net

(LIQD) to Present at LD Micro Conference

NEW YORK, Nov. 26, 2014  — Liquid Holdings Group, Inc. (Nasdaq:LIQD), a provider of cloud-based investment management solutions for the financial community, announced that its Chief Executive Officer, Brian Storms, will present at the LD Micro Conference on Thursday, December 4th at 1:30 P.M. Pacific Time (4:30 P.M. Eastern Time) in Los Angeles, California.

A live audio webcast and archive of the conference presentation will be available on the company’s website at http://ir.liquidholdings.com/events.cfm.

About Liquid Holdings Group

Liquid Holdings Group, Inc. (Nasdaq:LIQD) is a cloud-based technology and managed services provider to the global hedge fund and active trading markets. Liquid’s solutions are delivered efficiently and securely through the cloud in a SaaS model. The Liquid platform was purpose built to manage the entire trade lifecycle by seamlessly integrating multi-currency, multi-asset trade order management and execution with real-time risk, portfolio management and shadow account reporting through a single solution. The Company offers the Liquid platform or any of its components on a subscription basis to hedge fund managers, asset managers, family offices and financial institutions worldwide. Liquid was recently named 2014 Best Global Risk Management Software Company and Best USA Global Risk Management Software Company by the readers of Hedgeweek, as well as 2014 Best Cloud Provider and Best Fin Tech Operations Startup by FTF News.

Headquartered in New York City, Liquid Holdings Group was formed in 2012. For more information, please visit www.liquidholdings.com.

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.

CONTACT: Contact for Investor Relations:
         Monica Gould
         The Blueshirt Group
         +1 212 871-3927
         monica@blueshirtgroup.com

         Contact for Media Relations:
         Jon Schubin
         Cognito
         liquid@cognitomedia.com
         +1 646 395-6300

(BBLU) Completes $10 Million Private Placement

(RGLS) to Present at 26th Annual Piper Jaffray Healthcare, Genetic Rx Conference

LA JOLLA, Calif., Nov. 26, 2014  — Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 26^th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel on Wednesday, December 3, 2014 at 2:00 p.m. EST.  The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of Regulus’ website at www.regulusrx.com.  A replay of the webcast will be archived on Regulus’ website following the presentation date.

In addition, Paul Grint, M.D., Chief Medical Officer of Regulus, will participate in a panel discussion at the Genetic Rx Conference on Wednesday, December 3, 2014.  The conference is being held at the Joseph B. Martin Conference Center at Harvard Medical School.

About Regulus

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company.   Regulus has a well-balanced microRNA therapeutics pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection, and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy.  Regulus is also advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases.  Regulus’ commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca and Sanofi and a research collaboration with Biogen Idec focused on microRNA biomarkers.  In addition, the company has established Regulus microMarkers^SM, a division focused on identifying microRNAs as biomarkers of human disease, which is designed to support its therapeutic pipeline, collaborators and strategic partners.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus’ expectations regarding future therapeutic and commercial potential of Regulus’ business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus’ current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus’ programs are described in additional detail in Regulus’ SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(IRMD) Files 510(k) Submission for Premarket Notification

WINTER SPRINGS, Fla., Nov. 25, 2014  — IRADIMED CORPORATION (Nasdaq:IRMD), the only provider of non-magnetic intravenous (IV) infusion pump systems that are safe for use during magnetic resonance imaging (MRI) procedures, announced today that it has filed a submission for premarket notification under Section 510(k) of the Federal Food, Drug and Cosmetic Act with the US Food and Drug Administration (FDA) relating to its MRidium 3860+ MRI IV infusion pumps. This submission follows a September 2, 2014 announcement that the Company received a warning letter from the FDA requesting that it cease commercial distribution of its MRI IV infusion pumps and submit a 510(k). The Company’s President and CEO Roger Susi stated “following up our September 2^nd announcement of the FDA’s Warning Letter, we made a 510(k) submission to the agency yesterday with the tremendous combined efforts of many of the staff here at IRADIMED. We now look forward to having the 510(k) reviewed and cleared as expeditiously as possible. We continue to keep our potential and existing customers in close contact and maintain preparedness to resume domestic shipments as soon as clearance is received.”

Forward-Looking Statements

This press release includes forward-looking statements as defined in the Private Securities Litigation Act of 1995, particularly statements regarding expectations about future events affecting the Company and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond the Company’s control and could cause the Company’s actual results to differ materially and adversely from those expressed in its forward-looking statements as a result of various factors, including but not limited to: risks related to the Company’s assumptions regarding its ability to receive premarket clearance or successfully make a 510(k) submission, effectively respond to the warning letter, additional actions by or requests from the FDA and unanticipated costs or delays associated with resolution of these matters; as well as other factors discussed in the “Risk Factors” section of the Company’s most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. There can be no guarantee that the Company’s efforts will be successful and that it will be able to resume commercial distribution of its IV infusion pumps. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it does not know whether its expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. The Company does not undertake any obligation to update, amend or clarify these forward-looking statements or the “Risk Factors” contained in the Company’s most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

About IRADIMED CORPORATION

IRADIMED CORPORATION is the leading provider of non-magnetic IV infusion pump systems that are safe for use during MRI procedures. Electromechanical medical devices and pumps contain magnetic and electronic parts which generate radio frequency noise, create interference and are dangerous to operate in the presence of the powerful magnet which drives an MRI. The company’s mRidium (3850/3860+) IV pump systems have been designed with non-ferrous parts, ceramic ultrasonic motors, non-magnetic mobile stands and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. The company’s pump solution provides a seamless approach to providing IV fluids before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants must generally be sedated in order to remain immobile during an MRI scan. For more information please visit www.iradimed.com. mRidium is a trademark of IRADIMED CORPORATION.

CONTACT: Media Contact:
         Chris Scott
         Chief Financial Officer
         IRADIMED CORPORATION
         (407) 677-8022
         InvestorRelations@iradimed.com

(NERV) Appoints Dr. Remy Luthringer as CEO

WALTHAM, Mass., Nov. 25, 2014  — Minerva Neurosciences, Inc. (Nasdaq:NERV), today announced the appointment of Remy Luthringer, Ph.D., president and chief scientific officer of Minerva, to the additional post of chief executive officer of the company, replacing Rogerio Vivaldi, MD, who will be leaving the company by mutual agreement effective November 30, 2014. Dr. Luthringer will also become a member of the Board of Directors of Minerva Neurosciences effective immediately.

“We are very pleased that Remy Luthringer will assume the additional role of CEO at Minerva and that he will also now be a member of our Board of Directors. His extensive drug development experience is an ideal fit to position us to advance our promising research platforms at this stage,” said Marc Beer, chairman of Minerva’s Board of Directors. “On behalf of the entire Board, I would also like to thank Dr. Vivaldi for his dedication and all his contributions to Minerva, including the preparation and execution of the company’s IPO earlier this year.”

In his career, Dr. Luthringer has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system. He served as chief medical officer for Index Ventures, with a focus on investments in healthcare infrastructure. He was also the chief executive officer of the FORENAP Institute for Research in Neurosciences and Neuropsychiatry in France. Dr. Luthringer has extensive experience in clinical psychiatric practice and holds a Ph.D. in neurosciences and clinical pharmacology.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat neuropsychiatric diseases. Minerva is developing a portfolio of first-in-class proprietary compounds, including lead compound MIN-101, which is in Phase 2 trials for schizophrenia, and additional candidates targeting major depressive disorder (MDD), insomnia and other CNS disorders. Minerva’s common stock is listed on the NASDAQ Global Market where it trades under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com/.

Forward-Looking Safe-Harbor Statement:

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to management’s ability to successfully achieve its goals. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors including management’s ability to successfully achieve its goals. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the Securities and Exchange Commission on November 6, 2014. Copies of reports filed with the SEC are posted on our website. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

CONTACT: Media Contact:
         David Salisbury
         Berry & Company Public Relations
         Tel: 212-253-8881
         dsalisbury@berrypr.com

         Investor Contact:
         Renee Leck
         Stern Investor Relations
         Tel: 212-362-1200
         renee@sternir.com

(CXDC) to Participate in Benchmark Micro Cap Discovery Conference

HARBIN, China, Nov. 25, 2014  — China XD Plastics Company Limited (NASDAQ: CXDC, “China XD Plastics” or the “Company”), one of China’s leading specialty chemical producers engaged in the development, manufacture and sale of polymer composite materials primarily for automotive applications, today announced that Chief Financial Officer Taylor Zhang will host investor meetings at the Benchmark Micro Cap Discovery Conference, to be held at the Palmer House Hilton in Chicago, on Thursday, December 11, 2014.

Attendance at the conference is by invitation only for clients of The Benchmark Company. Please contact your Benchmark representative for conference registration information and to schedule a meeting with the Company.

About China XD Plastics Company Limited

China XD Plastics Company Limited, through its wholly-owned subsidiaries, develops, manufactures and sells polymer composite materials, primarily for automotive applications. The Company’s products are used in the exterior and interior trim and in the functional components of 25 automobile brands manufactured in China, including AUDI, BMW, Toyota, Buick, Mazda, and VW Passat, Golf and Jetta. The Company’s wholly-owned research center is dedicated to the research and development of polymer composite materials, and benefits from its cooperation with well-known scientists from prestigious universities in China. As of September 30, 2014, 311 of the Company’s products have been certified for use by one or more of the automobile manufacturers in China. For more information please visit http://www.chinaxd.net.

Contacts:

China XD Plastics
Mr. Taylor Zhang, CFO (New York)
Phone: +1 (212) 747-1118
Email: cxdc@chinaxd.net

ICR LLC

Mr. Gary Dvorchak, CFA (Beijing)
Senior Vice President
Phone (China): +86 (10) 6583-7500
Phone (US): +1 (310) 954-1123
Email: gary.dvorchak@icrinc.com

(RXDX) to Present at Upcoming Investor Conferences

Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that its management will be making company presentations at the following investor conferences in December 2014:

• The Piper Jaffray 26^th Annual Healthcare Conference at the Palace Hotel in New York, NY on December 2, 2014 at 9:30 a.m. Eastern time (presentation by Jonathan Lim, M.D., the company’s President and CEO); and
• The Oppenheimer & Co. 25th Annual Healthcare Conference at the Crowne Plaza Hotel in New York, NY on December 10, 2014 at 8:00 a.m. Eastern time (presentation by Jacob Chacko, M.D., the company’s CFO).

A webcast of each presentation will be available during the event in the Investors section of the company’s website at http://investor.ignyta.com, and will be archived and available at that site for 14 days.

About Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a precision oncology biotechnology company pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The company’s goal with this Rx/Dx approach is to discover, develop and commercialize new drugs that target activated cancer genes and pathways for the customized treatment of cancer. It aims to achieve this goal by pairing each of its product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients who are most likely to benefit from the precisely targeted drugs the company develops. For more information, please visit: www.ignyta.com.

(SCOK) Aboveground Facility At 100% Capacity, Generating 25k Cubic Meters of Syngas Per Hour

Company Serving Three Customers and Agents in Central Henan Province

PINGDINGSHAN, China, Nov. 25, 2014  — SinoCoking Coal and Coke Chemical Industries, Inc. (Nasdaq:SCOK), a producer of clean energy products located in Henan Province, today announced that its aboveground facility for the conversion of carbon dioxide into clean-burning syngas has achieved its initial production target of 25,000 cubic meters per hour and is currently transporting syngas to three customers and agents in and around its facility in Pingdingshan.

Based on the current price of $0.139 per cubic meter for syngas, the gross revenue generated per day by the aboveground facility is approximately $83,280. Gross profit margin is expected to be between 45% and 50%.

SCOK’s initial customers are Zhongshi Energy Co. Ltd., Henan Zhonghong Coal Chemical Industry Co., Ltd. and Baofeng County Bourui Technology Co., Ltd.

“We are pleased with the timely and successful start-up of what we believe is one of China’s first aboveground syngas facilities that can recycle carbon dioxide output to produce usable chemical compounds,” said SinoCoking Chairman and CEO Mr. Jianhua Lv. “As a result, SCOK now offers a clean energy alternative to both industrial and individual customers in our area, We are now preparing to start the next phase of construction at the facility that will further expand our capacity, and we expect to produce an additional 25,000 cubic meters per hour by the end of the first quarter of 2015.”

Mr. Lv further noted that while, initially, gas produced at the facility is directly transferred to customers via pipelines, the company is now working on introducing gas compression and refining technology into the syngas production process so that the end product can be stored in tanks and sold to customers as Compressed Natural Gas (CNG). As a clean-burning fuel, syngas is increasingly utilized as a clean-energy alternative to burning coal. Comprised primarily of hydrogen and carbon monoxide, syngas can also be used to produce a wide range of industrial products such as fertilizers, solvents, Liquid Natural Gas (LNG), CNG, and assorted synthetic materials.

According to the company, the new facility is one of the few in China that can produce 25,000 cubic meters of syngas per hour. Moreover, the company believes its new aboveground facility is the only one in China that combines coking and syngas.

For additional information on SinoCoking, please go to http://scokchina.com or refer to the company’s periodic reports filed with the Securities and Exchange Commission (http://www.scokchina.com/sec-filings.html). Investors wishing to receive SinoCoking’s corporate communications as they become available may go to the company’s Investor Relations site (http://www.scokchina.com/corporate-overview.html) and register under Email Alerts.

Also, investors may submit questions directly to Mr. Lv and his staff to receive non-confidential information about the company’s operations and products at the company’s “Ask Management” blog (http://www.scokchina.com/ask-management.html).

About SinoCoking

SinoCoking Coal and Coke Chemical Industries, Inc. (www.scokchina.com), a Florida corporation, is an emerging producer of clean energy products located in Pingdingshan, Henan Province, China. The company has historically been a vertically-integrated coal and coke processor of basic and value-added coal products for steel manufacturers, power generators, and various industrial users. SinoCoking has been producing metallurgical coke since 2002, and acts as a key supplier to regional steel producers in central China. SinoCoking also produces and supplies thermal coal to its customers in central China. SinoCoking currently owns its assets and conducts its operations through its subsidiaries, Top Favour Limited and Pingdingshan Hongyuan Energy Science and Technology Development Co., Ltd., and its affiliated companies, Henan Province Pingdingshan Hongli Coal & Coke Co., Ltd., Baofeng Coking Factory, Baofeng Hongchang Coal Co., Ltd., Baofeng Hongguang Environment Protection Electricity Generating Co., Ltd., Zhonghong Energy Investment Company, Henan Hongyuan Coal Seam Gas Engineering Technology Co., Ltd., Baofeng Shuangri Coal Mining Co., Ltd., and Baofeng Xingsheng Coal Mining Co., Ltd.

Forward-Looking Statements

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company’s financial position and business strategy. The words or phrases “plans,” “would be,” “will allow,” “intends to,” “may result,” “are expected to,” “will continue,” “anticipates,” “expects,” “estimate,” “project,” “indicate,” “could,” “potentially,” “should,” “believe,” “think,” “considers” or similar expressions are intended to identify “forward-looking statements.” These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

CONTACT: SinoCoking
         Song Lv, Chief Financial Officer
         + 86-375-2882-999
         lvsong@sinocoking.net
         http://www.scokchina.com/

         Investor Relations Counsel:
         Jimmy Caplan, Asia IR-PR
         +1-512-329-9505
         jimmy@asia-irpr.com
         http://asia-irpr.com/

(XOMA) to Present at the Piper Jaffray Healthcare Conference

BERKELEY, Calif., Nov. 24, 2014 — XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the Company’s Chief Executive Officer, is scheduled to present at the 26^th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014, at 9:30 a.m. ET.

A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA’s website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 60 days following the presentation.

About XOMA Corporation

XOMA’s innovative product candidates are the result of the Company’s expertise in developing allosteric modulating monoclonal antibodies, which has created opportunities to develop new classes of therapeutic antibodies with the potential to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program for Behçet’s disease uveitis, non-infectious uveitis, and pyoderma gangrenosum and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA’s scientific research also produced the XMet program, which consists of three classes of antibodies, including XOMA 358, an allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling, that could have a major effect on the treatment of abnormal metabolic states.

More detailed information can be found at www.xoma.com.

CONTACT: Company and Investor Contacts:
         Ashleigh Barreto
         510-204-7482
         barreto@xoma.com

         Juliane Snowden
         The Oratorium Group, LLC
         jsnowden@oratoriumgroup.com

(SYN) Safe-to-Proceed, IND Clinical Trials of SYN-004 In C. Diff

ROCKVILLE, Md., Nov. 24, 2014  — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that its Investigational New Drug (IND) application which was submitted to the U.S. Food and Drug Administration (FDA) in October will be proceeding into clinical trials for the development of the Company’s oral beta-lactamase enzyme SYN-004 for the prevention of Clostridium difficile (C. difficile) infection (CDI), antibiotic-associated diarrhea (AAD) and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous (IV) beta-lactam antibiotic therapy. Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end.

“We are pleased the FDA completed the 30-day review of our IND and to be initiating clinical trials of the first potential point-of-care preventative therapy for C. difficile, the CDC’s top-ranking public health threat,” said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. “Taking immediate and aggressive action to develop a therapy that can prevent C. difficile before it starts is critical in addressing this pervasive and life-threatening infection, and IND activation for SYN-004 is a key step toward the development and eventual commercialization of therapy to protect the millions of at risk U.S. patients.”

C. difficile is a widespread infection that occurs mostly in people who have had recent medical care with IV antibiotics. These antibiotics can create a harmful imbalance in the gut microbiome by killing “good” bacteria, giving C. difficile a chance to multiply and cause diarrhea, which can lead to dehydration, fever, abdominal pain, cramping, nausea, colitis, and even death. In all, 24 million Americans receive IV antibiotics annuallyⁱ, and the Company believes there is currently no vaccine or drug approved for the prevention of C. difficile infection.

SYN-004 is Synthetic Biologics’ oral drug candidate designed to be the first and only prophylactic treatment intended to prevent the development of C. difficile infection, by binding with and neutralizing certain common IV beta-lactam antibiotics in the gut. SYN-004 is intended to block the unintended harmful effects of antibiotics within the gastrointestinal (GI) tract, maintaining the natural balance of the bacterial flora (gut microbiome), potentially preventing the 1.1 million C. difficile infectionsⁱⁱ and 30,000 C. difficile-related deathsⁱⁱⁱ in the U.S. each year.

Mr. Riley added, “In addition to antibiotics being a key trigger in the development of C. difficile infection, research continues to point to the fact that disruption of the gut microbiome due to antibiotic usage, as well as the steady rise in antibiotic-resistant superbugs, are causative factors for a variety of GI, CNS and metabolic disorders, including obesity and diabetes. SYN-004 may be the solution.”

Synthetic Biologics has met each milestone for its C. difficile program leading up to the IND submission to the agency. Clinical drug manufacturing of SYN-004 under cGMP guidelines to support Synthetic Biologics’ planned Phase 1 and 2 clinical trials was completed on time to support the IND submission and clinical trial initiation. Most recently, the U.S. Patent and Trademark Office issued a Notice of Allowance for the first composition of matter patent application directly pertaining to SYN-004 in the U.S., which carries a patent term to at least 2031.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. The Company is developing an oral biologic to protect the gastrointestinal (GI) microflora from the effects of intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS) and a monoclonal antibody combination for the treatment of Pertussis being developed in collaboration with Intrexon Corporation (NYSE: XON). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the anticipated timing of the Synthetic Biologics’ clinical trials and data reports, intended benefits to be achieved from use of SYN-004, including the potential prevention of C. difficile infections, and the potential market for SYN-004. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics’ forward-looking statements include, among others, a failure to receive the necessary regulatory approvals for commercialization of Synthetic Biologics’ therapeutics, a failure of Synthetic Biologics’ clinical trials, and those conducted by investigators, to be commenced or completed on time or to achieve desired results, a failure of Synthetic Biologics’ clinical trials to receive anticipated funding, a failure of Synthetic Biologics’ products for the prevention and treatment of diseases to be successfully developed or commercialized, Synthetic Biologics’ inability to maintain its licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully commercialize products and other factors described in Synthetic Biologics’ report on Form 10-K for the year ended December 31, 2013 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

(FPRX) Clinical Collaboration With (BMY) On Opdivo and FPA008 in Six Tumor Types

NEW YORK and SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014  — Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R). The Phase 1a/1b study will evaluate the combination of Opdivo and FPA008 as a potential treatment option for patients with non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trademark for nivolumab.

Opdivo and FPA008 are part of a new class of cancer treatments known as immunotherapies that are designed to harness the body’s own immune system to fight cancer. Opdivo is approved in Japan for the treatment of patients with unresectable melanoma, and is being developed in multiple tumor types in more than 50 clinical trials. FPA008, in development as a potential treatment for rheumatoid arthritis (RA) and solid tumors, has initiated dosing for a Phase 1 clinical trial in RA. Preclinical data suggest that combining antibodies targeting PD-1 and CSF1R may lead to an enhanced anti-tumor immune response compared to either approach alone in treating cancer.

“This collaboration supports our strategy to expand the clinical development of Opdivo, including novel combination regimens and across numerous tumor types,” said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb. “We are excited to build upon our existing relationship with Five Prime Therapeutics in immuno-oncology, and explore the full potential of Opdivo and FPA008 in multiple tumor types.”

“We are pleased to establish a second collaboration with Bristol-Myers Squibb in the area of immuno-oncology,” said Lewis T. “Rusty” Williams, M.D., Ph.D., president and chief executive officer of Five Prime. “Their vision aligns with our commitment to advancing promising immune-modulating targets, alone or in combination, to create next-generation immunotherapies for cancer patients. We look forward to initiating this study and expanding the development of FPA008 as a potential immunotherapy for these six types of cancer.”

Under the terms of this agreement, Bristol-Myers Squibb will make a one-time payment of $30 million to Five Prime and will be responsible for study costs. Five Prime will conduct the clinical trial, which is expected to begin in 2015. The agreement provides for exclusivity with respect to the development, with a collaborative partner, of combination regimens of anti-PD-1/PDL1 antagonists together with an anti-CSF1R antagonist. Bristol-Myers Squibb will have a time-limited right of first refusal subject to certain conditions if Five Prime wishes to seek a partner for FPA008.

About Opdivo (nivolumab)

Cancer cells may exploit “regulatory” pathways, such as checkpoint pathways, to hide from the immune system and shield the tumor from immune attack. Opdivo is an investigational, fully-human PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T-cells.

Bristol-Myers Squibb has a broad, global development program to study Opdivoin multiple tumor types consisting of more than 50 trials – as monotherapy or in combination with other therapies – in which more than 7,000 patients have been enrolled worldwide. Among these are several potentially registrational trials in NSCLC, melanoma, renal cell carcinoma (RCC), head and neck cancer, glioblastoma and non-Hodgkin lymphoma (NHL).

In 2012, the FDA granted Fast Track designation for Opdivo in NSCLC, melanoma and RCC. In April 2014, the company initiated a rolling submission with the FDA for Opdivo in third-line pre-treated squamous cell NSCLC and expects to complete the submission by year-end. The FDA granted Opdivo Breakthrough Therapy Designation in May 2014 for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. On July 4, Ono Pharmaceutical Co. announced that Opdivo received manufacturing and marketing approval in Japan for the treatment of patients with unresectable melanoma, making Opdivo the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. On September 26, Bristol-Myers Squibb announced that the FDA accepted for priority review the Biologics License Application for previously treated advanced melanoma, and the Prescription Drug User Fee Act goal date for a decision is March 30, 2015. The FDA also granted Opdivo Breakthrough Therapy status for this indication. In the European Union, the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for Opdivo in advanced melanoma. The application has also been granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use. The EMA also validated for review the MAA for Opdivo in NSCLC.

About FPA008

FPA008, an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), blocks the activation and survival of monocytes and macrophages. Inhibition of CSF1R in inflamed RA joints blocks the production of inflammatory cytokines by macrophages and inhibits osteoclasts, monocyte-lineage cells that can cause bone erosions and joint destruction. Inhibition of CSF1R in many cancers reduces the number of immunosuppressive tumor-associated macrophages (TAMs), thereby facilitating an immune response against tumors.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime’s comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in cancer immunotherapy, an area of oncology with significant therapeutic potential and a growing focus of the company’s R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that nivolumab will receive regulatory approval in the U.S. either as a single agent or in a combination regimen, or, if approved, that it will become a commercially successful product. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2013 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Five Prime Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the planned clinical development of a combination of FPA008 and nivolumab. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACT: Bristol-Myers Squibb

         Media:
         Ken Dominski, 609-252-5251, ken.dominski@bms.com

         Investors:
         Ranya Dajani, 609-252-5330, ranya.dajani@bms.com
         Ryan Asay, 609-252-5020, ryan.asay@bms.com

         Five Prime Therapeutics:
         Amy Kendall, 415-365-5776, amy.kendall@fiveprime.com

(CIMT) To Be Acquired By (DDD)

ROCK HILL, S.C. and GIVAT SHMUEL, Israel, Nov. 24, 2014  — 3D Systems Corporation (NYSE:DDD) and Cimatron Ltd. (Nasdaq:CIMT) today announced a definitive agreement under which 3DS will acquire all of the outstanding shares of Cimatron for $8.97 per share in cash, subject to certain adjustments for Cimatron transaction expenses, for a total of approximately $97 million, inclusive of its net cash.

The combination of Cimatron’s products with 3DS’ portfolio, strengthens 3DS’ position in the fast-growing 3D design and manufacturing space. The transaction adds complementary products and technology and extends 3DS’ direct and reseller sales coverage globally. 3DS management expects the acquisition of Cimatron to be immediately accretive to its cash generation and to its Non-GAAP earnings per share upon closing.

“We believe that the perfect strategic fit between our businesses, combined with expanded capabilities in product development, channel coverage and marketing, could present sizeable synergies that together offer significant long-term customer benefits and shareholder value,” commented Avi Reichental, President and CEO of 3DS.

Cimatron is a leading provider of integrated 3D CAD/CAM software products and solutions for manufacturing. Cimatron’s products are used by a growing number of companies worldwide for their 3D production molds, tools and dies in a wide variety of functional end-use manufacturing applications. With two major product lines, CimatronE and GibbsCAM^®, Cimatron caters to all manufacturing sectors. CimatronE is an integrated CAD/CAM solution for toolmakers and manufacturers of discrete parts, which provides full associativity across the manufacturing process from quoting, through design and up to delivery. GibbsCAM, the CAM industry’s recognized ease-of-use leader, offers simple to use, yet extremely powerful, solutions for programming multi-axis CNC machine tools.

“We are delighted to combine our leading 3D CAD/CAM software products with 3DS’ expanding design and manufacturing digital thread,” said Danny Haran, CEO of Cimatron. “We have always been focused on providing comprehensive, cost-effective solutions that streamline manufacturing cycles and shorten product delivery time, and as part of 3DS we can substantially accelerate our progress and extend our reach and impact.”

“Our entire Board of Directors is proud of Cimatron and its management’s long term success in building a great company with leading products that create sustained customer and shareholder value, and are grateful to have been part of guiding this journey,” added Yossi Ben Shalom, Chairman of the Board of Cimatron.

The transaction is subject to customary closing conditions, including requisite regulatory approvals and the approval of Cimatron’s shareholders. The Boards of Directors of both companies have unanimously approved the proposed transaction. The companies expect the transaction to close in the first quarter of 2015.

Advisors

Needham & Company is serving as financial advisor to 3DS. Hunton & Williams LLP and Gornitzky & Co. are serving as 3DS’ legal counsel.

Prometheus Financial Advisory is serving as financial advisor to Cimatron. Meitar Liquornik Geva Leshem Tal is serving as Cimatron’s legal counsel.

Forward-Looking Statements

Certain statements made in this press release that are not statements of historical or current facts, including statements regarding the expected timetable for completing the proposed transaction, benefits and synergies of the proposed transaction, future opportunities for the combined company and products, future financial performance and any other statements regarding 3DS’ and Cimatron’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts, are forward-looking statements within the meaning of the federal securities laws. Forward-looking statements often use words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “goal”, “believe”, “hope”, “aim”, “continue”, “will”, “may”, “would”, “could” or “should” or other words of similar meaning or the negative thereof. These statements are subject to numerous risks and uncertainties, many of which are beyond the companies’ control, which could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: failure to obtain the required votes of Cimatron’s shareholders; the timing to consummate the proposed transaction; satisfaction of the conditions to closing of the proposed transaction may not be satisfied or that the closing of the proposed transaction otherwise does not occur; the risk that a regulatory approval that may be required for the proposed transaction is not obtained or is obtained subject to conditions that are not anticipated; the diversion of management time on transaction-related issues; the ultimate timing, outcome and results of integrating the operations of Cimatron; the effects of the business combination of 3DS and Cimatron, including the combined company’s future financial condition, results of operations, strategy and plans; expected synergies and other benefits from the proposed transaction and the ability of 3DS to realize such synergies and other benefits; expectations regarding regulatory approval of the transaction; results of litigation, settlements, and investigations; the availability and alternative uses of 3DS’ cash; actions by third parties, including governmental agencies; protection of intellectual property rights and against cyber attacks; compliance with environmental laws; changes in government regulations and regulatory requirements; risks of international operations, including risks relating to unsettled political conditions, war, the effects of terrorism, and foreign exchange rates and controls, international trade and regulatory controls. The factors described under the headings “Forward-Looking Statements,” “Cautionary Statements and Risk Factors,” and “Risk Factors” in 3DS’ report on Form 10-K for the year ended December 31, 2013 and Cimatron’s report on Form 20-F for the year ended December 31, 2013, and other U.S. Securities and Exchange Commission (the “SEC”) filings of 3DS and Cimatron discuss some of the important risk factors identified that may affect these factors and 3DS’ and Cimatron’s respective business, results of operations and financial condition. 3DS and Cimatron undertake no obligation to revise or update publicly any forward-looking statements for any reason. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

About 3D Systems

3DS is pioneering 3D printing for everyone. 3DS provides the most advanced and comprehensive 3D design-to-manufacturing solutions including 3D printers, print materials and cloud sourced custom parts. Its powerful digital thread empowers professionals and consumers everywhere to bring their ideas to life in material choices including plastics, metals, ceramics and edibles. 3DS’ leading healthcare solutions include end-to-end simulation, training and integrated 3D planning and printing for personalized surgery and patient specific medical and dental devices. Its democratized 3D design and inspection products embody the latest perceptual, capture and touch technology. Its products and services replace and complement traditional methods with improved results and reduced time to outcomes. These solutions are used to rapidly design, create, communicate, plan, guide, prototype or produce functional parts, devices and assemblies, empowering customers to manufacture the future.

Leadership Through Innovation and Technology

• 3DS invented 3D printing with its Stereolithography (SLA) printer and was the first to commercialize it in 1989.
• 3DS invented Selective Laser Sintering (SLS) printing and was the first to commercialize it in 1992.
• 3DS invented the ColorJet Printing (CJP) class of 3D printers and was the first to commercialize 3D powder-based systems in 1994.
• 3DS invented MultiJet Printing (MJP) printers and was the first to commercialize it in 1996.
• 3DS Medical Modeling pioneered virtual surgical planning (VSP) and its services are world-leading, helping many thousands of patients on an annual basis.

Today its comprehensive range of 3D printers is the industry’s benchmark for production-grade manufacturing in aerospace, automotive, patient specific medical device and a variety of consumer, electronic and fashion accessories.

More information on 3DS is available at www.3dsystems.com.

About Cimatron

Cimatron is a leading provider of 3D CAD/CAM software for the manufacturing industry. With two major product lines, GibbsCAM and CimatronE, Cimatron caters to all manufacturing sectors, offering specialized solutions for mold and die makers, as well as solutions for multi-Axis production milling and turning.

Ranked among the top CAD/CAM suppliers in every global region, Cimatron has subsidiaries in Asia, North America and Europe, and works with certified independent service providers in over 40 countries worldwide. Cimatron service providers offer responsive and effective sales and technical support, helping businesses use Cimatron software to maximize their potential.

Cimatron’s full range of products and solutions use the most advanced technology available to speed up productivity and shorten delivery times. Designed and developed by manufacturers and toolmakers with a wealth of experience on the shop floor, both of Cimatron’s product lines are easy to learn and intuitive for the manufacturing professionals who use them.

More information is available at www.cimatron.com.

Additional Information

In connection with the proposed transaction, Cimatron intends to mail a proxy statement to its shareholders and furnish a copy of the proxy statement with the SEC on Form 6-K. Shareholders of Cimatron are urged to read the proxy statement and the other relevant material when they become available because they will contain important information about Cimatron, 3DS, the proposed transaction and related matters. Shareholders are urged to read carefully the proxy statement and other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction. The proxy statement (when available) may be obtained for free at the SEC website at www.sec.gov.

This press release is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell shares of Cimatron. Cimatron, its executive officers and directors may be deemed to be participants in the solicitation of proxies from shareholders of Cimatron in connection with the proposed transaction. Information about those executive officers and directors of Cimatron and their ownership of Cimatron shares is set forth in Cimatron’s proxy statement for its special meeting of shareholders scheduled for 6-Jan-2015, which will be furnished to the SEC on Form 6-K. Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed transaction will be included in the proxy statement that Cimatron intends to furnish to the SEC on Form 6-K.

CONTACT: Investor Contact:
         Stacey Witten
         Email: Stacey.Witten@3dsystems.com

         Media Contact:
         Alyssa Hoyt
         Email: Press@3dsystems.com

(RNA) Acquisition By (BMRN) Includes Duchenne Muscular Dystrophy Products

• Acquisition of Prosensa provides near-term opportunity to commercialize, if approved, its exon-skipping drug candidate,drisapersen, for Duchenne muscular dystrophy (DMD)
• Drisapersen is currently under a rolling review as part of a New Drug Application process and has Orphan, Fast Track and Breakthrough Therapy designation by the FDA
• Drisapersen, a potential first-to-market and best-in-class product for treating a large population of patients with a rare, fatal genetic disease represents up to 10,000 DMD patients
• Follow-on products leveraging Prosensa’s same technology platform in the pipeline target an additional 35,000 DMD patients in BioMarin’s commercial territories
• Investor conference call to be held today, November 24, 2014 at 5am PST (8am EST)

SAN RAFAEL, Calif., Nov. 24, 2014  — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Prosensa Holding N.V. (Nasdaq:RNA) today announced that they have entered into a definitive agreement in which BioMarin will offer to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016 and Europe no later than February 15, 2017, respectively.

“BioMarin is dedicated to the rare disease community, and the acquisition of Prosensa fits strategically with our mission of delivering therapies that address serious unmet medical needs,” said Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin. “We are committed to working closely with regulatory authorities worldwide in bringing a potentially breakthrough therapy to patients with this devastating condition.”

Mr. Bienaimé continued, “We will leverage our experience at developing rare disease therapies to achieve regulatory approvals and bring drisapersen to market as quickly as possible. Further, if we are successful in advancing drisapersen to early regulatory approvals, we believe this transaction would be accretive to operating and GAAP profitability in 2017.”

Pat Furlong, President and Founder of Parent Project Muscular Dystrophy said, “BioMarin has a successful track record of developing new therapies for people with devastating disorders and for effectively collaborating with health authorities and patient communities. We look forward to working with BioMarin to bring new treatments to boys with Duchenne and other forms of muscular dystrophy.”

Under the terms of the definitive agreement, BioMarin will offer to acquire all of Prosensa’s issued and outstanding ordinary shares and all ordinary share equivalents in an all cash transaction for $17.75 per share for an upfront purchase price of approximately $680 million. Prosensa shareholders may also receive two regulatory milestone payments of approximately $80 million for receiving approval in the U.S. no later than May 15, 2016 and in Europe no later than February 15, 2017, respectively. In addition, within 5 business days of signing the purchase agreement BioMarin will purchase from Prosensa a $50 million convertible note.  If the transaction fails to close for any reason, the note will automatically convert into 4,395,914 shares of Prosensa’s stock.

The transaction is expected to be accounted for as a business combination. BioMarin will maintain operations at Prosensa’s headquarters, based in Leiden, The Netherlands and integrate Prosensa personnel from that office.

The acquisition will provide BioMarin with worldwide rights to multiple orphan-drug candidates, including drisapersen, which is currently under rolling review as part of a New Drug Application (NDA) with the Food and Drug Administration. Prosensa’s pipeline is comprised of several potential products that leverage their proprietary RNA-modulating technology platform for the treatment of various genotypes of Duchenne muscular dystrophy and other genetic disorders.

Hans Schikan, Chief Executive Officer of Prosensa added, “BioMarin has established itself as a leader in rare diseases, characterized by strong management, thorough execution, and a resounding commitment to patients in developing and commercializing treatments where there is a high unmet medical need. This transaction will enhance Prosensa’s mission by bringing innovative therapies to patients across the world as quickly and efficiently as possible. The deal also creates shareholder value by positioning Prosensa’s strong portfolio of orphan drug candidates for future success with a prominent rare disease company that has the experience and dedication to bring drisapersen and our follow-on compounds to the hands of patients who desperately need them.”

BioMarin will effect the transaction primarily through a tender offer for all of the issued and outstanding Prosensa ordinary shares (the “Offer”) and expect to close in the first quarter of 2015. The commencement of the Offer will be subject to having obtained workers council advice, and the consummation of the Offer is subject to the satisfaction of customary closing conditions for a transaction of this nature, including the tender of at least 80% of the issued and outstanding Prosensa ordinary shares and the receipt of regulatory clearance. Following completion of the Offer, the Supervisory Board of Prosensa will consist of five individuals designated by BioMarin and two individuals who currently serve on the Supervisory Board of Prosensa, who will act as independent directors. The two independent directors will, in accordance with Dutch practice, act as independent supervisory directors to protect the interest of any minority shareholders until BioMarin utilizes certain available reorganization structures available under Dutch law to acquire full ownership of Prosensa’s outstanding shares and/or its business. An Extraordinary General Meeting will be convened in connection with the Offer and to adopt, among other things, certain resolutions relating to the reorganization of Prosensa.

About Exon skipping

Synthetic oligonucleotides can bind to specific regions of pre-mRNA to induce exon skipping or exon inclusion, reduce mutated toxic RNA or protein, remove specific protein domains, or block protein expression. Exon skipping can restore the proper reading frame to the dystrophin mRNA, allowing shorter but still functional dystrophin protein to be produced, potentially maintaining or improving muscle function in people with DMD.

About Drisapersen

Drisapersen induces the skipping of dystrophin exon 51, potentially providing a therapeutic benefit to DMD patients for whom skipping of exon 51 restores the proper dystrophin reading frame, corresponding to approximately 13% of DMD patients.   Drisapersen has been administered to over 300 patients in seven clinical studies. It is generally well tolerated, with an adverse event (AE) profile consistent with this class of molecule. Drisapersen is currently under rolling review as part of a New Drug Application (NDA) with the Food and Drug Administration.

About Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) is the most common fatal genetic disorder diagnosed in childhood, affecting approximately 1 in every 3,500 live male births (about 20,000 new cases each year). DMD is caused by a mutation in the gene that encodes for dystrophin, a protein that is important in connecting the cytoskeleton of muscle fibers to the extracellular matrix. Its deficiency in DMD leads to progressive muscle weakness, loss of ambulation in early adolescence, and typically death due to pulmonary or cardiac insufficiency in the late twenties. Because the Duchenne gene is found on the X-chromosome, it primarily affects boys; however, it occurs across all races and cultures.  There is currently no cure for DMD.

About Prosensa

Prosensa N.V. is a biotechnology company based in Leiden, The Netherlands, which discovers and develops RNA-modulating therapeutics for the treatment of genetic disorders. The primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including DMD, myotonic dystrophy and Huntington’s disease. Prosensa’s lead compound for DMD, is drisapersen. Its seven follow-on programs for other DMD genotypes are currently in various stages of development from preclinical through Phase 2. In addition, the Company has preclinical products in development for Huntington’s disease and myotonic dystrophy. The Company has 85 employees.

About Parent Project Muscular Dystrophy

Duchenne is a fatal genetic disorder that slowly robs young men of their muscle strength. Parent Project Muscular Dystrophy (PPMD) is the largest most comprehensive nonprofit organization in the United States focused on finding a cure for Duchenne muscular dystrophy, the mission is to end Duchenne.

PPMD invests deeply in treatments for this generation of young men affected by Duchenne and in research that will benefit future generations. They advocate in Washington, DC, and have secured hundreds of millions of dollars in funding.  PPMD demands optimal care, and strengthens, unite and educate the global Duchenne community.

Everything they do and everything they have done since their founding in 1994—helps boys with Duchenne live longer, stronger lives. They will not rest until every young man has a treatment to end Duchenne. Go to www.ParentProjectMD.org for more information or to learn how you can support the efforts and help families affected.

Conference Call Details

BioMarin will host a conference call and live audio webcast today at 5am PST/8am EST to discuss the transaction. The live audio webcast will be available via the Investors and Media section of the BioMarin Pharmaceutical website at www.BMRN.com. Interested parties may now access the PowerPoint presentation that will be used for the call at the same URL. A replay will be available for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. Approved products include: Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Powder for Oral Solution and Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; Firdapse® (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS); and VIMIZIM® (elosulfase alfa) for the treatment of Morquio A (MPS IVA). Product candidates include: BMN 165 (PEGylated recombinant phenylalanine ammonia lyase), also referred to as PEG PAL, which is currently in Phase 3 clinical development for the treatment of PKU; talazoparib (BMN 673), a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 3 clinical development for the treatment of germline BRCA breast cancer; BMN 701, a novel fusion of acid alpha glucosidase (GAA) with a peptide derived from insulin like growth factor 2, which is currently in Phase 3 clinical development for the treatment of Pompe disease; BMN 111, a modified C-natriuretic peptide, which is currently in Phase 2 clinical development for the treatment of achondroplasia; and BMN 190, a recombinant human tripeptidyl peptidase-1 (rhTPP1), which is currently in Phase 1 for the treatment of late-infantile neuronal ceroid lipofuscinosis (CLN2), a form of Batten Disease. For additional information, please visit www.BMRN.com. Information on BioMarin’s website is not incorporated by reference into this press release.

BioMarin Forward Looking Statements

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the possible purchase of Prosensa Holding N.V.; the development of drisapersen if the purchase closes; the potential of drisapersen of the purchase closes; and the potential market for drisapersen. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: possible competitive offers for the acquisition of Prosensa; actions by Prosensa’s shareholders at the extraordinary general meeting of Prosensa and in the tender process; results and timing of current and planned preclinical studies and clinical trials of drisapersen; our ability to successfully manufacture drisapersen; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning drisapersen; the market for each the product; and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission, including, without limitation, the risk factors contained under the caption “Risk Factors” in BioMarin’s 2013 Annual Report on Form 10-K, and the factors contained in BioMarin’s reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

Additional Information

The Offer described in this communication has not yet commenced, and this communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any ordinary shares of Prosensa or any other securities. On the commencement date of the Offer, a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, will be filed with the United States Securities and Exchange Commission (the “SEC”). Thereafter, Prosensa will file a solicitation/recommendation statement on 14D-9 with the SEC.  The solicitation and offer to purchase ordinary shares of Prosensa will only be made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO.

Investors and security holders of Prosensa are urged to read both the schedule to (and the included offer to purchase) and the solicitation/recommendation statement, as they may be amended from time to time and other relevant documents filed with the SEC when they become available before they make any decision with respect to the tender offer, because they will contain important information about the terms of the offer, the proposed transactions and the parties thereto.

Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the tender offer that will be named in the tender offer statement.

Prosensa Cautionary Statement Regarding Forward-Looking Statements

Some of the statements contained in this communication are forward-looking statements, including statements regarding the expected consummation of the transaction, which involves a number of risks and uncertainties, including the satisfaction of closing conditions for the acquisition, such as regulatory approval for the transaction, and the tender of at least eighty percent of the outstanding ordinary shares of the company, the possibility that the transaction will not be completed and other risks and uncertainties discussed in the Prosensa’s public filings with the SEC, including the “Risk Factors” section of Prosensa’s annual report on Form 20-F for the year ended December 31, 2013, as well as the tender offer documents to be filed by BioMarin and the solicitation/recommendation statement to be filed by Prosensa.  These statements are based on current expectations, assumptions, estimates and projections, and involve known and unknown risks, uncertainties and other factors that may cause results, levels of activity, performance or achievements to be materially different from any future statements. These statements are generally identified by words or phrases such as “believe”, “anticipate”, “expect”, “intend”, “plan”, “will”, “may”, “should”, “estimate”, “predict”, “potential”, “continue,” or the negative of such terms or other similar expressions. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results and/or timing discussed in the forward-looking statements, and you should not place undue reliance on these statements. Prosensa disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.

CONTACT: Investors
         Traci McCarty
         BioMarin Pharmaceutical Inc.
         (415) 455-7558

         Media
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

(NETE) TOT Money Signs Financing Agreement with Bank Otkritie

Factoring with Russian bank supports mobile payment growth initiatives

MIAMI, Nov. 24, 2014  — Net Element, Inc. (NASDAQ: NETE) (“the Company”), a technology-driven group specializing in mobile payments and value-added transactional services in emerging countries and in the United States, announces that its indirect Russian subsidiary, OOO TOT Money (“TOT Money”), has entered into a financing agreement with Bank Otkritie Financial Corp. (“Bank Otkritie”), one of Russia’s largest private listed banks.  This financing is complementary to the Company’s Alfa-Bank factoring facility and provides additional flexibility and capacity to expand our presence in Russia’s transactional services market.  In conjunction with the Alfa-Bank factoring agreement, TOT Money will have approximately $15 million of available credit to help fund its growth.

Per the three-year Agreement, TOT Money will assign to Bank Otkritie its accounts receivable as security for financing in an aggregate amount of up to 200 million Russian rubles (approximately USD $4.2 million based on the currency exchange rate as of the close of business November 17, 2014) provided by Bank Otkritie to TOT Money. Included in this Agreement, Moscow-based Bank Otkritie will track the status of TOT Money’s account receivables, monitor timeliness of payment of such accounts receivable, and provide related services.  Oleg Firer, Net Element chief executive officer, stated, “This financing agreement provides TOT Money with an added measure of flexibility and foundation needed to advance its position in the Russian mobile payments industry. We’re honored to partner with Bank Otkritie as we continue to grow this business and look forward to the opportunities which it provides.”

Additional information regarding this financing may be found in Net Element’s 8K, which was filed with the Securities and Exchange Commission (SEC) on November 19, 2014, and may be obtained from the SEC’s Internet website at http://www.sec.gov.

About Bank Otkritie Financial Corp.

Bank Otkritie is a full-service financial corporation offering retail, corporate and institutional clients a wide range of bank, investment, insurance and pension plan solutions. The bank operates mostly in Russia and has also been successful in developing its business in the U.S. and the UK.

Bank Otkritie’s investment unit ranks among leading Russian companies on the London Stock Exchange and is one of the top three largest investment companies on the Moscow Stock Exchange in terms of turnover.  More information is available at: http://www.otkritie.com/en.

About Net Element

Net Element (NASDAQ: NETE) is a global technology-driven group specializing in mobile payments and value-added transactional services. The Company owns and operates a global mobile payments and transaction processing provider, TOT Group. TOT Group companies include Unified Payments, recognized by Inc. Magazine as the #1 Fastest Growing Private Company in America in 2012; Aptito, a next generation cloud-based point of sale payments platform; and TOT Money, which has been ranked as the #1 SMS content provider by Russia’s second largest telecommunications operator. Together with its subsidiaries, Net Element enables ecommerce and adds value to mobile commerce environments. Its global development centers and high-level business relationships in the United States, Russia and Commonwealth of Independent States strategically position the Company for continued growth. Net Element has U.S. headquarters in Miami and headquarters in Moscow. More information is available at www.netelement.com.

Forward-Looking Statements                                   


This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, whether Net Element or its business continues to grow and whether the financing secured by Net Element will be adequate to meet the Company’s objectives.  All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) Net Element ‘s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element ‘s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element ‘s ability to successfully expand in existing markets and enter new markets; (iv) Net Element ‘s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element ‘s business; (viii) changes in government licensing and regulation that may adversely affect Net Element ‘s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element ‘s business; (x) Net Element ‘s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk that the U.S. government may decide to impose sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K and the subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

(NEPT) Jim Hamilton Appointed President & CEO of Neptune

Seasoned Leader in Development, Manufacturing, Marketing and Sales of Nutraceutical Products

LAVAL, Quebec, Nov. 21, 2014  — Neptune Technologies & Bioressources Inc. (“Neptune” or the “Corporation”) (Nasdaq:NEPT) (TSX:NTB), announces that its Board of Directors has appointed Jim Hamilton as President and Chief Executive Officer of Neptune and a member of the Board, effective February 2, 2015.

Mr. Hamilton is currently Vice President Human Nutrition and Health, North America, and President of DSM Nutritional Products USA, Inc., based in Parsippany, New Jersey. He serves on the global management team of DSM Nutritional Products’ Human Nutrition & Health business, an organization with over $2 billion in global sales and operations in more than 40 countries. DSM Nutritional Products is an important division of the life sciences and material sciences corporation, DSM N.V. of the Netherlands.

Mr. Hamilton’s industry knowledge has made him a valuable contributor to several trade associations and he is the immediate past chairman of the Board of Directors of the Council for Responsible Nutrition (CRN), the dietary supplement industry’s leading trade association. Jim is a graduate of Concordia University in Montreal, Canada and he has attended a number of business education and leadership programs at the London Business School and INSEAD.

“As Neptune begins a new era, Jim is the right person to lead the Corporation forward into its next phase of growth and success,” highlighted Mr. Pierre Fitzgibbon, Chairman of Neptune’s Board of Directors. “I have known Jim for a number of years and he is an excellent fit, bringing complementary abilities to the current management team, including strong human resources skills, a key ingredient for a leader.”  Furthermore, Jim is a proven executive with a deep understanding of the nutraceutical market, strong industry connections and over 25 years of experience, working in the United States, Europe and Canada. During his career, he played a leading role in the development, manufacturing, marketing and sales of dietary supplement, food, animal feed, and personal care products.

“I am pleased and excited to be given the opportunity to take Neptune to the next level as it solidifies its supply chain and reaffirms its market leadership,” said Mr. Hamilton. “Neptune’s new state-of-the-art plant and innovative offerings, combined with a fast growing consumer base looking for health and wellness products, puts the Corporation in a solid position for growth. I look forward to working with the management team and Board to further develop Neptune’s business and drive profitable growth.”

“On behalf of the Board of Directors, I would also like to thank Andre Godin for his leadership in this transition period,” continued Mr. Fitzgibbon. “Andre has been instrumental to the firm’s progress, including steering the Corporation through a difficult phase while production was down and successfully reestablishing operations at its Sherbrooke plant.  He will continue to act as Interim President and CEO until Jim’s arrival in February 2015, following which he will remain a key member of the executive team.”

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids (”PUFAs”). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune’s distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune’s products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune’s head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.

Neptune holds approximately 48% of the participating and voting rights of Acasti Pharma Inc. (“Acasti”) and 95% of the voting rights of NeuroBioPharm Inc. (“NeuroBio”). Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBioPharm respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti’s lead prescription drug candidate is CaPre^®, a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

Forward Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties,  readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the “Cautionary Note Regarding Forward-Looking Information” section contained in Neptune’s latest Annual Information Form, which also forms part of Neptune’s latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune’s website at www.neptunebiotech.com (the “AIF”). All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under “Risk Factors”.

Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.

CONTACT: Neptune Contacts:

         Andre Godin
         Interim CEO and CFO
         +1.450.687.2262
         a.godin@neptunebiotech.com
         neptunebiotech.com

         John Ripplinger
         Investor Relations
         +1.450.687.2262
         j.ripplinger@neptunebiotech.com
         neptunebiotech.com

(XXII) to Hold Conference Call to Provide Business Update For Investors

22nd Century Group, Inc. (NYSE MKT:XXII) announced today that Henry Sicignano III, President and Chief Operating Officer of 22nd Century Group, together with Richard M. Sanders, an independent Director of 22nd Century Group, will provide a business update for investors on Tuesday, November 25^th at 10:00 AM (EST).

The conference call is expected to reach hundreds of participants from the investment sector and tobacco industry. Chardan Capital Markets Senior Research Analyst, James McIlree, will moderate the call. Interested parties are invited to participate in the call by dialing: (888) 438-5525 and using Conference ID 6119197.

The conference call will consist of a brief overview of recent business highlights and a summary of the Company’s plans for the first half of 2015. Immediately thereafter, there will be a question and answer segment open to all callers.

Henry Sicignano stated, “We believe that recent changes by 22nd Century that place primary focus on near-term revenue opportunities will be beneficial to the Company and to shareholder value. Accordingly, we are pleased to be able to provide a business update to increase awareness about our Company and to describe our excellent business prospects.”

For additional information, please visit: www.xxiicentury.com

22nd Century Group to Present at LD Micro Investor Conference on December 3rd

Separately, 22nd Century announced today that the Company will be a featured presenter at the LD Micro Investor Conference in Los Angeles, California. Mr. Sicignano will make a presentation to institutional investors and high net worth retail investors at this invitational conference on Wednesday, December 3rd, 2014 at 9:30 AM PST / 12:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles.

“We are honored to have 22nd Century Group present at the conference,” stated Chris Lahiji, President of LD Micro.

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. The Company’s technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant. 22nd Century owns or is the exclusive licensee of 129 issued patents in 78 countries plus an additional 51 pending patent applications; 22nd Century also holds co-exclusive rights to another 16 patent applications. Goodrich Tobacco is focused on commercial tobacco products and potentially less harmful cigarettes. Botanical Genetics is focused on novel cannabis plant varieties and on cannabis-based products. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2013, filed on January 30, 2014, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

(AMCN) and China Telecom Partner to Offer In-flight Connectivity

BEIJING, Nov. 21, 2014 — AirMedia Group Inc. (“AirMedia” or the “Company”) (Nasdaq: AMCN), a leading operator of out-of-home advertising platforms in China targeting mid-to-high-end consumers, today announced that it has entered into a strategic partnership agreement with China Telecom Satellite Communications Co. Ltd. (“CTSAT”), a wholly-owned subsidiary of China Telecom that specializes in satellite communications operations, to jointly develop and operate a network for in-flight satellite connectivity services and multimedia cabin entertainment on airplanes.

According to the strategic partnership agreement, CTSAT agrees to provide the Company with, under the same conditions, priority access to satellite and on-the-ground network and operation services for developing and operating secure, reliable, and consistent in-flight connectivity in compliance with the laws and regulations of China.

“The strategic partnership with CTSAT is crucial and instrumental for us to further increase our market share of the in-flight Wi-Fi sector in China. So far, CTSAT is the only operator of in-flight satellite communications in China duly licensed by the competent authority in China. Our strategic partnership with CTSAT is another example of our strong capability in integrating varies parts of the value chain to provide a comprehensive solution to airlines and their customers,” commented Mr. Herman Guo, chairman and chief executive officer of AirMedia. “We have made substantial progress on our transformation to an in-flight and on-train Wi-Fi operator. We have already obtained a leading position in the on-train Wi-Fi sector in China. We expect to also establish a leading position in in-flight Wi-Fi business in China leveraging our long-term relationship with airlines, years of operation experiences on advertising in the air travel sector, our extensive contents and copyrights in the air sector, and our business chain integration capability.”

About AirMedia Group Inc.

AirMedia Group Inc. (Nasdaq: AMCN) is a leading operator of out-of-home advertising platforms in China targeting mid-to-high-end consumers. AirMedia operates the largest digital media network in China dedicated to air travel advertising. AirMedia operates digital frames in 26 major airports and digital TV screens in 26 major airports, including most of the 30 largest airports in China. In addition, AirMedia sells advertisements on the routes operated by seven airlines, including the four largest airlines in China. In selected major airports, AirMedia also operates traditional media platforms, such as billboards and light boxes, and other digital media, such as mega-size LED screens.

In addition, AirMedia has obtained exclusive contractual concession rights until the end of 2020 to develop and operate outdoor advertising platforms at Sinopec’s service stations located throughout China.

For more information about AirMedia, please visit http://www.airmedia.net.cn.

About China Telecom Satellite Communications Co. Ltd

Dedicated to satellite communications services, China Telecom Satellite Communications Co. Ltd, as a wholly-owned subsidiary of China Telecom, specializes in the operation of its parent corporation’s satellite communications business. It serves as the resource center, product integration center and professional support center of China Telecom’s satellite communications business, mainly engaged in Satellite mobile communications, VSAT communications, International private line and Satellite broadband access, etc. Providing integrated (Aviation/Land) satellite communications and broadcasting operating service with characteristics to subscribers.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expect,” “anticipate,” “future,” “intend,” “plan,” “believe,” “estimate,” “confident” and similar statements. Among other things, the Business Outlook section and the quotations from management in this announcement, as well as AirMedia Group Inc.’s strategic and operational plans, contain forward-looking statements. AirMedia may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about AirMedia’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to: if advertisers or the viewing public do not accept, or lose interest in, AirMedia’s air travel advertising network, AirMedia may be unable to generate sufficient cash flow from its operating activities and its prospects and results of operations could be negatively affected; AirMedia derives most of its revenues from the provision of air travel advertising services, and any slowdown in the air travel advertising industry in China may materially and adversely affect its revenues and results of operations; AirMedia’s strategy of expanding its advertising network by building new air travel media platforms and expanding into traditional media in airports may not succeed, and its failure to do so could materially reduce the attractiveness of its network and harm its business, reputation and results of operations; if AirMedia does not succeed in its expansion into gas station, in-flight internet services and in-air multimedia platformor other outdoors media advertising, its future results of operations and growth prospects may be materially and adversely affected; if AirMedia’s customers reduce their advertising spending or are unable to pay AirMedia in full, in part or at all for a period of time due to an economic downturn in China and/or elsewhere or for any other reason, AirMedia’s revenues and results of operations may be materially and adversely affected; AirMedia faces risks related to health epidemics, which could materially and adversely affect air travel and result in reduced demand for its advertising services or disrupt its operations; if AirMedia is  unable to retain existing concession rights contracts or obtain new concession rights contracts on commercially advantageous terms that allow it to operate its advertising platforms, AirMedia may be unable to maintain or expand its network coverage and its business and prospects may be harmed; a significant portion of AirMedia’s revenues has been derived from the six largest airports and four largest airlines in China, and if any of these airports or airlines experiences a material business disruption, AirMedia’s ability to generate revenues and its results of operations would be materially and adversely affected; AirMedia’s limited operating history makes it difficult to evaluate its future prospects and results of operations; and other risks outlined in AirMedia’s filings with the U.S. Securities and Exchange Commission. AirMedia does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Investor Contact:

Raymond Huang
Senior Director of Investor Relations
AirMedia Group Inc.
Tel: +86-10-8460-8678
Email: ir@airmedia.net.cn

(ADAT) to Present at LD Micro Conference on December 3

BERKLEY HEIGHTS, N.J., Nov. 21, 2014  — Authentidate Holding Corp. (Nasdaq:ADAT), a provider of secure web-based software applications and telehealth products and services for healthcare organizations, today announced that Mr. O’Connell “Ben” Benjamin, Chief Executive Officer, will present at the LD Micro Conference at 11:30 a.m. (PT), Track 2, on Wednesday, December 3, 2014. The conference will be held December 2-4, 2014 at the Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, CA. The Company’s group presentation will be available for the public to access at http://wsw.com/webcast/ldmicro7/adat and on the Company’s website at http://www.authentidate.com/investors. This webcast will be archived for 90 days following the live presentation. Authentidate management will be available during the day on December 3 for one-on-one meetings. Please contact LD Micro to schedule a meeting.

“We are honored to have Authentidate Holding Corp. present at the Main Event this year,” stated Chris Lahiji, Founder of LD Micro.

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.

About Authentidate Holding Corp.

Authentidate Holding Corp. is a provider of secure web-based software applications and telehealth products and services that enable healthcare organizations to coordinate care for patients and enhance related administrative and clinical workflows. Authentidate’s products and services enable healthcare organizations to increase revenues, reduce costs and enhance patient care by eliminating paper and manual work steps from clinical and administrative processes. Authentidate’s telehealth solutions combine patient vital signs monitoring with a web application that streamlines patient care management. Delivered as Software as a Service (SaaS), customers only require an Internet connection and web browser to access our web-based applications thereby utilizing previous investments in systems and technology. The company’s healthcare customers and users include leading homecare companies, health systems, physician groups and governmental entities. These organizations utilize the company’s products and services to coordinate care for patients outside of acute-care.

For more information, visit the company website www.authentidate.com

Authentidate, Inscrybe and InscrybeMD are registered trademarks of Authentidate Holding Corp. All other trade names are the property of their respective owners.

CONTACT: Media Contacts:

         James Carbonara, Hayden IR, james@haydenir.com
         or (646) 755-7412
         Brett Maas, Hayden IR, Brett@haydenir.com
         or (646) 536-7331

(EIGI) Prices Public Offering of 13M Shares of Common Stock

BURLINGTON, Mass., Nov. 21, 2014  — Endurance International Group Holdings, Inc. (Nasdaq:EIGI), a leading provider of cloud-based platform solutions designed to help small and medium-sized businesses succeed online, today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $14.50 per share.

In the offering, Endurance is selling 3,000,000 shares of common stock, with net proceeds to Endurance of approximately $41.3 million, after deducting underwriting discounts and commissions and estimated offering expenses, and certain existing stockholders are selling 10,000,000 shares of common stock. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,950,000 shares of common stock. Endurance will not receive any proceeds from the sale of shares of common stock by the selling stockholders. The offering is expected to close on or about November 26, 2014, subject to customary closing conditions.

Endurance expects to use the net proceeds from the offering for general corporate purposes, which may include the repayment and refinancing of debt, working capital and capital expenditures. In addition, Endurance believes that opportunities may exist from time to time to expand its current business through acquisitions of or investments in complementary companies, businesses, products or technologies. While Endurance has no current agreements, commitments or understandings for any specific acquisitions or investments at this time, Endurance may use a portion of the net proceeds for these purposes.

Goldman, Sachs & Co. and Credit Suisse Securities (USA) LLC are acting as lead joint book-running managers. Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC are also acting as book-running managers. Allen & Company LLC, Cowen and Company, LLC, Jefferies LLC, Craig-Hallum Capital Group LLC and Oppenheimer & Co. Inc. are acting as co-managers.

The securities described above are being offered by Endurance pursuant to a Form S-3 registration statement initially filed with the Securities and Exchange Commission (SEC) on November 7, 2014. The registration statement was amended on November 17, 2014 and contained a preliminary prospectus relating to the shares of common stock sold in this offering and was declared effective by the SEC on November 20, 2014. A final prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov or from Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, email: prospectusny@ny.email.gs.com or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010, telephone: (800) 221-1037, email: newyork.prospectus@credit-suisse.com.

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cautionary Note on Forward-Looking Statements

This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts, and statements identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “confident,” “positions,” and variations of such words or words of similar meaning. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that these plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks set forth under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2014 filed with the SEC on November 7, 2014 and other reports we file with the SEC. We assume no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

About Endurance International Group

Endurance International Group (Nasdaq:EIGI) helps small and medium-sized business owners establish, manage and grow their businesses by harnessing the power and promise of the web. As a leading provider of cloud-based platform solutions to help small and medium-sized business owners succeed online, Endurance, through its family of brands – including Bluehost, HostGator, iPage, Domain.com, A Small Orange, and ResellerClub – supports over 3.8 million subscribers and is able to tailor solutions for small businesses at every stage and level of sophistication. Endurance is headquartered in Burlington, Massachusetts, has a presence in Asia and the Americas, and employs over 2,400 people. For more information, visit endurance.com.

Endurance International Group and the compass logo are trademarks of The Endurance International Group, Inc. Other brand names of Endurance International Group are trademarks of The Endurance International Group, Inc. or its subsidiaries.

CONTACT: Investor Contact:
         Angela White
         Endurance International Group
         (781) 852-3450
         ir@endurance.com

         Press Contact:
         Dani LaSalvia
         Endurance International Group
         (781) 852-3212
         press@endurance.com

(CJJD) Record Online Sales on “Singles Day China,” 265% Revenue Increase

HANGZHOU, China, Nov. 20, 2014  — China Jo-Jo Drugstores, Inc. (NASDAQ CM: CJJD) (the “Company”), a leading China-based retail and wholesale distributor of pharmaceutical and healthcare products through its own retail and online pharmacies, today announced its online pharmacy posted the largest one-day sales on Singles Day China, or the Black Friday China (“Singles Day”), November 11, 2014 with total revenue increased by 265% year over year, on a one-day sales comparison basis.

In order to encourage online shopping, since 2009, large online retailers in China such as Tmall.com (“Tmall”) of Alibaba Group Holdings (NYSE: BABA), China’s largest B2C online retailer and JD.com (NASDAQ: JD) (“JD”) have started to make various discount sales on November 11 every year. November 11, also called Singles Day, has become the largest online commercial event in China.

Highlights of the Company’s online pharmacy sales on Singles Day include:

• Total one-day sales revenue reached approximately $521,000 (RMB3.21 million), a 265% increase from the sales record on the same day of the prior year. The result vastly exceeded the Company’s targeted sales goal of approximately $325,000 (RMB2 million). The number of one-day online purchase orders increased 328% over the same day last year. In comparison, our regular daily online sale averaged at approximately $42,000 (RMB 0.26 million) in October 2014, an increase of more than 250% from the same month in 2013.
• More than 90% of the Company’s online sales were generated from our online pharmacy at Tmall, the Company’s online stores at JD and YHD.com. The Company’s official website generated the remaining sales.
• As of October 2014, our online pharmacy was ranked 10th on Tmall.com in the Pharmacy and Health Goods category

“We are very encouraged to see a great increase of our online pharmacy sales during the Singles Day online shopping festival this year. We will continue to offer quality and safe products on our e-commerce platform, and provide a better shopping experience to our customers,” commented Mr. Liu, Lei, Chairman and CEO of China Jo-Jo Drugstore. “Looking ahead, the dramatic increase of our online pharmacy sales on Tmall encourages us to further pursue our online growth strategy which we believe to be one of biggest opportunities for us in 2015 and beyond.”

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and healthcare products in China. As of September 30, 2014, the Company had 51 retail pharmacies in Hangzhou. The Company’s wholesale subsidiary not only supplies its retail stores, but also distributes drug and other healthcare products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).

Forward Looking Statement

Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” “anticipate,” the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company’s internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements.

Contacts

China Jo-Jo Drugstores, Inc.
Ming Zhao
Chief Financial Officer
Tel: (561) 372-5555
Email: frank.zhao@jojodrugstores.com

(TGEN) Sale of Two InVerde Ultra Units Expected to Provide $225K in Energy Savings per Year

WALTHAM, Mass., Nov. 20, 2014  — Tecogen^® Inc. (NASDAQ: TGEN) today announced the sale of two Ultra™ InVerde^® INV-100 combined heat and power (CHP) systems to a 37 story Art Deco Style skyscraper in Manhattan’s Financial District. The net projected energy savings from the Tecogen equipment is $225K per year.

Tecogen’s two systems are expected to generate more than 70% of the building’s energy needs, significantly reducing energy costs, and cutting criteria pollutants, the compounds contributing to smog. The new system is estimated to reduce the annual carbon output attributed to the residence by 640 tons of CO₂.

All Systems Cogeneration designed and is managing the residential project.  As a successful Tecogen associate, All Systems Cogeneration has sold more than 50 Tecogen systems over time.

“Tecogen provides what we look for in a vendor; high quality, reliable, dependable systems,” said Gregg Giampaolo, president of All Systems Cogeneration, the NY state based firm.  “In terms of the nuts and bolts of our business, Tecogen makes it easy.  They provide excellent factory support from available parts to accessible engineering support.”

“Long term relationships with companies such as All Systems Cogeneration allow us to grow our business exponentially,” said Robert Panora, Tecogen’s President and Chief Operating Officer. “Their market knowledge with sales and engineering capabilities make All Systems Cogeneration a contributor to Tecogen’s growth.”

In addition to cost savings, the Tecogen systems provide the building with stand-by power when grid power is lost.

About Tecogen

Tecogen manufactures, installs, and maintains high efficiency, ultra-clean combined heat and power products including natural gas engine-driven cogeneration, air conditioning systems, and high-efficiency water heaters for industrial and commercial use. Tecogen has shipped more than 2,000 units, supported by an established network of engineering, sales, and service personnel across the United States. For more information, please visit www.tecogen.com.

Tecogen Media Contact Information:
David Garrison
P: 781-466-6403
E: David.Garrison@Tecogen.com

Tecogen Investor Contact Information:
John N. Hatsopoulos
P: 781-622-1120
E: jhatsopoulos@tecogen.com